4,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by nVerses Capital LLC

nVerses Capital LLC bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 4,500 shares of the company’s stock, valued at approximately $301,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after acquiring an additional 5,129,800 shares in the last quarter. Capital World Investors grew its stake in Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after buying an additional 18,728 shares during the last quarter. Mawer Investment Management Ltd. raised its holdings in Moderna by 6.7% in the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after acquiring an additional 120,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after acquiring an additional 463,960 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after purchasing an additional 29,566 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $54.10 on Friday. Moderna, Inc. has a 12-month low of $53.55 and a 12-month high of $170.47. The stock has a 50-day simple moving average of $70.75 and a 200 day simple moving average of $104.56. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $20.73 billion, a price-to-earnings ratio of -3.45 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. During the same period in the prior year, the business earned ($3.62) earnings per share. On average, research analysts anticipate that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MRNA shares. TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and cut their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Finally, Leerink Partners reduced their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $97.18.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the completion of the sale, the director now directly owns 2,224,015 shares of the company’s stock, valued at $266,792,839.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,184 shares of company stock worth $3,804,931. Insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.